613660-87-0

Basic information

• Product Name: 4-(Aminosulfonyl)phenylboronic acid
• Synonyms: 4-SULFAMOYLPHENYLBORONIC ACID;4-AMINOSULFONYLPHENYLBORONIC ACID;(4-AMINOSULPHONYL)BENZENEBORONIC ACID;4-BORONOBENZENESULFONAMIDE;4-(Aminosulphonyl)benzeneboronic acid 97%;4-(Aminosulfonyl)benzeneboronic acid;4-(Aminosulphonyl)benzeneboronic acid ,97%;4-Sulphamoylbenzeneboronic acid 97%
• CAS NO: 613660-87-0
• Molecular Formula: C₆H₈BNO₄S
• Molecular Weight: 201.01
• Product Categories: blocks;BoronicAcids;Sulfonamides;API intermediates;Boronate Ester;Boronic Acid;Potassium Trifluoroborate
• Mol File: 613660-87-0.mol
• Article Data: 3

Chemical Properties

• Melting Point: 250-256
• Boiling Point: 461.944 °C at 760 mmHg
• Flash Point: 233.176 °C
• Appearance: /
• Density: 1.54 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.618
• Storage Temp.: 2-8°C
• PKA: 7.85±0.16(Predicted)
• CAS DataBase Reference: 4-(Aminosulfonyl)phenylboronic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(Aminosulfonyl)phenylboronic acid(613660-87-0)
• EPA Substance Registry System: 4-(Aminosulfonyl)phenylboronic acid(613660-87-0)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36-20/21/22
• Safety Statements: 26-36/37
• WGK Germany: 3
• Hazardous Substances Data: 613660-87-0(Hazardous Substances Data)

Usage

Uses

4-Sulfamoylbenzeneboronic acid is used as pharmaceutical intermediate.

InChI:InChI=1/C6H8BNO4S/c8-13(11,12)6-3-1-5(2-4-6)7(9)10/h1-4,9-10H,(H2,8,11,12)

Upstream product

• 1033691-63-2 C₆H₆BF₃NO₂S^(1-) 
• 701-34-8 4-bromo-benzenesulfonic acid amide 
• 98-58-8 4-bromobenzenesulfonyl chloride 
• 208516-15-8 4-(tert-butylaminosulphonyl)benzeneboronic acid 

Downstream Products

• 355400-08-7 [7-chloro-2-oxo-6-(4-sulfamoyl-phenyl)-1,2-dihydro-quinolin-3-yl]-phosphonic acid diethyl ester 
• 21821-40-9 5-(4-aminosulfonylphenyl)furan-2-carbaldehyde 
• 765938-44-1 3-[5-(4-aminosulfonylphenyl)-2-furyl]acrylic acid 
• 1206797-73-0 C₂₂H₁₉NO₅S₃ 
• 1206797-77-4 C₂₂H₁₉NO₅S₃ 
• 1206797-79-6 C₂₃H₂₁NO₆S₃ 
• 1206797-81-0 C₂₃H₂₁NO₆S₃ 
• 181695-72-7 valdecoxib 
• 1287769-35-0 benzyl 2,5-dihydro-4-(4-sulfamoylphenyl)-3-phenyl-5-methyl-2H-isoxazole-2-carboxylate 
• 1313603-02-9 4-{[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)ethyl]amino}benzenesulfonamide 

Relevant articles and documents

Discovery of novel potent and highly selective glycogen synthase kinase-3β (GSK3β) inhibitors for Alzheimers Disease: Design, synthesis, and characterization of pyrazines

Glycogen synthase kinase-3β, also called tau phosphorylating kinase, is a proline-directed serine/threonine kinase which was originally identified due to its role in glycogen metabolism. Active forms of GSK3β localize to pretangle pathology including dystrophic neuritis and neurofibrillary tangles in Alzheimers disease (AD) brain. By using a high throughput screening (HTS) approach to search for new chemical series and cocrystallization of key analogues to guide the optimization and synthesis of our pyrazine series, we have developed highly potent and selective inhibitors showing cellular efficacy and bloo-brain barrier penetrance. The inhibitors are suitable for in vivo efficacy testing and may serve as a new treatment strategy for Alzheimers disease.

2,3,5-TRISUBSTITUTED PYRIDINES AS INHIBITORS OF CYCLOOXYGENASE-2

The invention encompasses the novel compound of Formula (I) as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula (I). The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula (I).